Compare BKT & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKT | DTIL |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.5M | 362.6M |
| IPO Year | 1994 | 2019 |
| Metric | BKT | DTIL |
|---|---|---|
| Price | $9.58 | $7.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $29.40 |
| AVG Volume (30 Days) | 105.9K | ★ 402.8K |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.42 | $3.53 |
| 52 Week High | $11.23 | $11.29 |
| Indicator | BKT | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 37.23 | 48.99 |
| Support Level | $9.50 | $6.12 |
| Resistance Level | $9.69 | $7.80 |
| Average True Range (ATR) | 0.12 | 0.93 |
| MACD | -0.04 | -0.22 |
| Stochastic Oscillator | 10.73 | 17.63 |
Blackrock Income Trust Inc is a closed-end management investment company. Its investment objective is to manage a portfolio of high-quality securities to achieve both preservation of capital and high monthly income. The fund seeks to achieve its investment objective by investing at least 65% of its assets in mortgage-backed securities.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).